Skip to main content

GATC Biotech expands oncology product line with INVIEW ONCOPANEL for solid tumour profiling

Press Release   •   May 11, 2016 13:00 BST

INVIEW ONCOPANEL extending GATC Biotech's oncology product line
  • Surveillance of 50 clinically relevant cancer genes for targeted treatment of solid tumours
  • Treatment decision support for clinicians for a personalised therapy
  • Direct comparative studies now possible with a set of cancer-specific genes for DNA from tumour tissue or for circulating tumour DNA from liquid biopsy samples


Constance, Germany, May 11th, 2016: GATC Biotech, a leading provider of advanced genome analysis and diagnostic services, launched today INVIEW ONCOPANEL, a comprehensive multigene cancer panel for solid tumour profiling. The next-generation sequencing (NGS)-based panel consists of 50 cancer-specific genes that could add diagnostic, prognostic and therapeutic value to personalised care. 


INVIEW ONCOPANEL was the lone missing member of our cancer research and diagnostics portfolio,” said Dr Markus Benz, COO of GATC Biotech. “The service perfectly complements our liquid biopsy-based assay GATCLIQUID ONCOPANEL. It enables researchers and clinicians to screen not only liquid biopsy samples, but also tissue biopsy samples for genomic alterations. These carefully selected genes can help characterise a patient’s tumour and identify the most suitable treatment course on a case-by-case basis.”


With the rising need for validation of non-invasive liquid biopsies, researchers can now evaluate the concordance in mutation profiles from tumour tissue samples with INVIEW ONCOPANEL and from liquid biopsy samples with GATCLIQUID ONCOPANEL. Both cancer sets consist of more than 200 clinically actionable regions on 50 cancer-specific genes with strong predictive and prognostic potential. The targeted cancer-related genes include well-known tumour activators, tumour suppressors and biomarkers of drug resistance.


“By providing cost-efficient detection of mutations in key cancer drivers, we hope to draw the most meaningful molecular information out of invasive, but necessary tissue biopsies,” added Dr Benz. “With the ability to perform comparative studies on tumour tissue and plasma-based patient samples under diagnostic conditions, we also aim to contribute evidence to proof-of-concept studies that are needed to implement liquid biopsies in clinical settings.”


INVIEW ONCOPANEL, which is a standardised sample-to-data solution, applies proprietary protocols for low-input DNA extraction from precious formalin-fixed, paraffin-embedded (FFPE) or fresh tissue samples. Optimised workflows carried out on leading technologies consistently result in extraordinarily high sequence coverage, uniformity and sensitivity that are needed to profile solid tumours and support tailored treatment decisions with absolute confidence.

GATC Biotech, a family owned business since 1990, is Europe’s leading sequencing services provider with more than 10,000 customers from academia, healthcare and industry worldwide. The company consistently contributes to the sequencing field with innovative products, scientific expertise and rigorous quality. Currently, the entrepreneurial energy is concentrated on a completely new approach in the area of personalised medicine. GATCLIQUID is the world’s first liquid biopsy- based service for cancer research and diagnosis.

As a renowned brand, GATC Biotech offers all leading sequencing technologies in its own laboratories in Cologne and Constance, Germany. The company’s proprietary workflows deliver ready-for-diagnostics results backed by ISO 17025 accreditation and ISO 13485 certification. From Sanger to next-generation sequencing, GATC Biotech offers unmatched flexibility to customers interested in any kind of genomics such as transcriptome, epigenome, exome or whole genome analysis.

GATC Biotech has a proven record of publicly funded projects by the EU and other national agencies. The company has formed numerous successful collaborations with world-renowned universities, academic institutions, pharmaceutical and biotechnological companies.

Please visit www.gatc-biotech.com for more information about genomic innovation – Made in Germany.

Attached Files

PDF document

Comments (0)

Add comment

Comment